Tiludronic acid
 | |
|---|---|
| Systematic (IUPAC) name | |
| {[(4-Chlorophenyl)thio]methylene}bis(phosphonic acid) | |
| Clinical data | |
| Trade names | Skelid |
| AHFS/Drugs.com | International Drug Names |
| Legal status | ? |
| Identifiers | |
| CAS number | 89987-06-4  |
| ATC code | M05BA05 |
| PubChem | CID 60937 |
| DrugBank | DB01133 |
| UNII | 6PNS59HP4Y  |
| KEGG | D08599 |
| ChEMBL | CHEMBL1350 |
| Chemical data | |
| Formula | C7H9ClO6P2S |
| Mol. mass | 318.609 g/mol |
| (what is this?) (verify) | |
Tiludronic acid (INN; also known as tiludronate) is a bisphosphonate used for treatment of Paget's disease of bone (osteitis deformans) in human medicine. It has the tradename Skelid. In veterinary medicine, tiludronic acid is used to treat navicular disease and bone spavin in horses. Its tradenames are Tildren and Equidronate.
Administration
In human medicine, tiludronic acid is administered orally. The recommended dose is a single 400 mg daily oral dose, taken with 6 to 8 ounces of plain water only, should be administered for a period of 3 months. Beverages other than plain water (including mineral water), food, and some medications are likely to reduce absorption.
In horses, tiludronic acid is administered by IV infusion as absorption by oral route is very poor. The recommended dose is 1 mg/kg mixed with saline. The infusion should last at least 30 mn to avoid side effects.
External links
| ||||||||||||||||